Skip to main content
Erschienen in: Clinical and Translational Oncology 6/2018

23.10.2017 | Correspondence

Comment on “Serum human epididymis protein 4 is associated with the treatment response of concurrent chemo-radiotherapy and prognosis in patients with locally advanced non-small cell lung cancer” by Lan WG et al.

verfasst von: G. Yavas, C. Yavas, S. Akyurek

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Excerpt

To the editor, …
Literatur
1.
Zurück zum Zitat Lan WG, Hao YZ, Xu DH, Wang P, Zhou YL, Ma LB. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer. Clin Transl Oncol. 2016;18(4):375–80.CrossRefPubMed Lan WG, Hao YZ, Xu DH, Wang P, Zhou YL, Ma LB. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer. Clin Transl Oncol. 2016;18(4):375–80.CrossRefPubMed
2.
Zurück zum Zitat Zhong H, Qian Y, Fang S, Yang L, Li L, Gu W. HE4 expression in lung cancer, a meta-analysis. Clin Chim Acta. 2017;470:109–14.CrossRefPubMed Zhong H, Qian Y, Fang S, Yang L, Li L, Gu W. HE4 expression in lung cancer, a meta-analysis. Clin Chim Acta. 2017;470:109–14.CrossRefPubMed
3.
Zurück zum Zitat Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;6(7):61.CrossRef Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;6(7):61.CrossRef
4.
Zurück zum Zitat Nagy B Jr, Bhattoa HP, Steiber Z, Csobán M, Szilasi M, Méhes G, et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clin Chem Lab Med. 2014;52(11):1639–48.CrossRefPubMed Nagy B Jr, Bhattoa HP, Steiber Z, Csobán M, Szilasi M, Méhes G, et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clin Chem Lab Med. 2014;52(11):1639–48.CrossRefPubMed
5.
Zurück zum Zitat Nagy B Jr, Krasznai ZT, Balla H, Csobán M, Antal-Szalmás P, Hernádi Z, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012;49(Pt 4):377–80.CrossRefPubMed Nagy B Jr, Krasznai ZT, Balla H, Csobán M, Antal-Szalmás P, Hernádi Z, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012;49(Pt 4):377–80.CrossRefPubMed
Metadaten
Titel
Comment on “Serum human epididymis protein 4 is associated with the treatment response of concurrent chemo-radiotherapy and prognosis in patients with locally advanced non-small cell lung cancer” by Lan WG et al.
verfasst von
G. Yavas
C. Yavas
S. Akyurek
Publikationsdatum
23.10.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 6/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1775-2

Weitere Artikel der Ausgabe 6/2018

Clinical and Translational Oncology 6/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.